[Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer's disease].

Selezneva ND, Roshchina IF, Korovaitseva GI, Gavrilova SI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2018Cited by 1 (Europe PMC)

PMID30499493DOI10.17116/jnevro201811810130PepBankPUB-30499493

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In first-degree relatives of Alzheimer's disease patients, a positive CGI effect was reported in 77.6% after Cerebrolysin treatment.
In plain wordsIn relatives of Alzheimer's disease patients, 77.6% showed a positive clinical impression score response after Cerebrolysin treatment.
Peptide
Cerebrolysin
Outcome
IncreaseCGI positive response
Study
n = 67
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 ml/day · intravenous · 1 monthAs given in this study (human).
Measurements
Positive CGI effect
77.6%
Relatives
Source sentences
Summary
The positive effect of course treatment on the CGI was established in 77.6% of the relatives.
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline.
Summary · context
The duration of treatment was 1 month.
Report a problemFND-3049949301
02HumanNon-randomized trialEfficacy outcome
In relatives without cognitive difficulties, MMSE scores significantly improved after Cerebrolysin treatment.
In plain wordsIn relatives without cognitive difficulties, MMSE scores improved after Cerebrolysin treatment.
Peptide
Cerebrolysin
Outcome
IncreaseMMSE score without cognitive difficulties
Study
n = 40
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 ml/day · intravenous · 1 monthAs given in this study (human).
Source sentences
Summary
The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline.
Summary · context
The duration of treatment was 1 month.
Report a problemFND-3049949304
03HumanNon-randomized trialEfficacy outcome
In relatives without cognitive difficulties, MoCA scores significantly improved after Cerebrolysin treatment.
In plain wordsIn relatives without cognitive difficulties, MoCA scores improved after Cerebrolysin treatment.
Peptide
Cerebrolysin
Outcome
IncreaseMoCA score without cognitive difficulties
Study
n = 40
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 ml/day · intravenous · 1 monthAs given in this study (human).
Source sentences
Summary
The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline.
Summary · context
The duration of treatment was 1 month.
Report a problemFND-3049949305
04HumanNon-randomized trialEfficacy outcome
In relatives with confirmed cognitive difficulties, MMSE scores significantly improved after Cerebrolysin treatment.
In plain wordsIn relatives with confirmed cognitive difficulties, MMSE scores improved after Cerebrolysin treatment.
Peptide
Cerebrolysin
Outcome
IncreaseMMSE score with confirmed cognitive difficulties
Study
n = 27
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 ml/day · intravenous · 1 monthAs given in this study (human).
Source sentences
Summary
The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline.
Summary · context
The duration of treatment was 1 month.
Report a problemFND-3049949302
05HumanNon-randomized trialEfficacy outcome
In relatives with confirmed cognitive difficulties, MoCA scores significantly improved after Cerebrolysin treatment.
In plain wordsIn relatives with confirmed cognitive difficulties, MoCA scores improved after Cerebrolysin treatment.
Peptide
Cerebrolysin
Outcome
IncreaseMoCA score with confirmed cognitive difficulties
Study
n = 27
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 ml/day · intravenous · 1 monthAs given in this study (human).
Source sentences
Summary
The scores on the MMSE and MoCA scales were significantly improved in the group with cognitive difficulties objectively confirmed by the clinical/neuropsychological examination (n=27) and in the group without cognitive difficulties (n=40).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-seven relatives (mean age 57.6±14.2 y.o.) received cerebrolysin in the dose of 20 ml/day in intravenous drips in 100 ml isotonic saline.
Summary · context
The duration of treatment was 1 month.
Report a problemFND-3049949303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.